Nguyen Anh Tu 4

What Happened

• Nguyen Anh Tu, Chief Medical Officer of Xeris Biopharma (XERS), was granted a total of 283,455 equity awards on 2026-01-30: 121,293 shares (direct award) and 162,162 shares classified as a derivative award. Each award was granted at $0.00 (no cash paid) and is reported with a total transaction value of $0. These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: January 30, 2026; Form 4 filed February 2, 2026 (timely filing).
• Grant details: 121,293 shares + 162,162 derivative units = 283,455 total awards; per-share price reported $0.00.
• Vesting: Footnote indicates these awards are restricted stock units (RSUs) that vest in equal annual installments over three years, subject to continued employment.
• Other holdings notes: Footnote also references 3,030 shares acquired 12/31/2025 under the company ESPP and a disclaimer of beneficial ownership (reporting person disclaims beneficial ownership except to extent of pecuniary interest).
• The filing excerpt does not list the total shares beneficially owned after these grants in the provided data.

Context

• These are compensation grants (awards), which are routine for executives and do not represent open-market buying or selling. The derivative/RSU awards are contingent rights to receive shares upon vesting, not immediate stock sales or option exercises.